Latest Posts

• Biotech Roundup: Gottlieb v. Juul, Solid Slumps, Avidity Gets $100M & More

  Lung injuries connected to the use of electronic cigarettes have topped 2,000 and killed 40 people, according to the Centers for Disease Control and Prevention.

  It’s still unclear whether the cases are tied to legally sold products or devices modified by... Read more »

  Sarah de Crescenzo11/15/19

• Daré to Add Microchip-Based Birth Control to Women’s Health Portfolio

  The list of activities our smartphones can control grows daily. Transfer money? It’s simple. Order groceries? That, too. Turn off the bedroom lights? Check.

  How about contraception?

  Advancing new forms of birth control is a central focus at Daré Bioscience (NASDAQ:... Read more »

  Sarah de Crescenzo11/15/19

• Avidity Bio Adds $100M to Advance R&D of Muscle Disorder Drugs

  Earlier this year, Avidity Biosciences and Eli Lilly began a partnership to develop new drugs based on the biotech’s technology for delivering genetic material to cells. On Wednesday, Lilly was among a group of investors that joined a $100 million financing... Read more »

  Frank Vinluan11/13/19

• Neuroscience Is Taking the Spotlight at Xconomy’s Bay Area Xchange

  These are heady times for neuroscience research. Startups developing new approaches to brain disorders are raising money to advance their discoveries toward clinical trials. One failed neuro drug is getting another shot.

  On Nov. 19 in San Francisco, we’ll... Read more »

  Frank Vinluan11/11/19

• Bio Roundup: Feds Sue Gilead, Biogen Eyes China, CRISPR’d Kidneys & More

  During the state of the union address this year, President Trump pledged to end HIV transmission within the next decade. A key part of that plan is an HIV prevention drug made by Gilead Sciences. That drug has now become the... Read more »

  Frank Vinluan11/8/19

• AstraZeneca Chooses China for R&D and AI Centers, $1B Biotech Fund

  AstraZeneca says it will establish centers for drug research and artificial intelligence development in China. The pharmaceutical giant has also set up a $1 billion fund to foster biotech innovation in that country.

  The move—which was announced at the China International... Read more »

  Gareth Macdonald11/6/19

• GE Healthcare Opens Startup Labs at Former AstraZeneca UK R&D Site

  The doors have opened at a GE Healthcare-supported open-access lab for startups at AstraZeneca’s former global center for oncology research and development at Alderley Park, the largest bioscience research campus in the UK.

  The AstraZeneca (NYSE: AZN) site in Macclesfield,... Read more »

  Dan Stanton11/6/19

• Biotech Roundup: Novartis on Hold, AMAG Vote, Neuro News & More

  The brain has stymied many efforts to develop new neuroscience drugs, leading a number of big pharmaceutical companies to pull back on such R&D work. This week, Amgen joined them.

  Amgen (NASDAQ: AMGN) is ending its research and early development... Read more »

  Frank Vinluan11/1/19

• FDA Halts Novartis Gene Therapy Study Amid Animal Safety Concerns

  Novartis must stop enrollment of a clinical trial testing its gene therapy for a rare, muscular disorder after safety concerns surfaced in data from an animal study.

  The FDA put a partial clinical hold on a Phase 1/2 study testing the... Read more »

  Frank Vinluan10/30/19

• Bio Roundup: Biogen’s Reversal, FDA Moves Fast, a CF Cocktail & More

  Earlier this year, it seemed that companies testing Alzheimer’s disease treatments based on a long-held hypothesis as to its cause—brain deposits of a protein called beta amyloid—were giving up the ghost.

  Biogen (NASDAQ: BIIB) was among them. The drug maker... Read more »

  Sarah de Crescenzo10/25/19

• Bio Roundup: Ichnos Emerges, Beyond CAR-T, BridgeBio Bails & More

  New brand-name drugs typically grab the life science headlines. A venture capital firm will invest tens of millions to develop one and a pharmaceutical company hopes to recoup hundreds of millions by selling it. But a shortage of one particular chemotherapy... Read more »

  Frank Vinluan10/18/19

• Eli Lilly Drug Acquired in Armo Deal Fails Pancreatic Cancer Test

  An experimental drug that was the centerpiece of a $1.6 billion Eli Lilly acquisition last year has now failed a pivotal test in pancreatic cancer.

  Eli Lilly (NYSE: LLY) said Wednesday that patients treated with its drug candidate pegilodecakin, plus... Read more »

  Frank Vinluan10/16/19

• FDA OKs Lilly’s Lasmiditan, First New Acute Migraine Drug in Decades

  Eli Lilly won FDA approval for a migraine drug on Friday, giving the pharmaceutical giant a second medication that addresses the condition that causes millions of people to experience severe headaches and other debilitating symptoms.

  The FDA approved the drug, lasmiditan... Read more »

  Frank Vinluan10/11/19

Load More News ›

• Bio Roundup: Nobel Prizes, Placebo Effect Rises, ICER’s Fire & More

  Congrats to this year’s Nobel Prize winners in medicine… although, we have to ask: For the US researchers who are honored, isn’t there something crushing about a call in the middle of the night from Sweden, interrupting a dream about... Read more »

  Alex Lash10/11/19

• The Placebo Effect Is Hobbling New Psychiatric Drugs. What Can Stop It?

  Sixteen years ago, Kim Witczak’s husband died by his own hand, turning her world upside down. He had just begun taking an antidepressant off-label for insomnia, and she believes an undisclosed side effect of the drug drove him to suicide. Compelled... Read more »

  Alex Lash10/10/19

• Nobel Prize in Medicine Goes to 3 Who Showed How Cells Sense Oxygen Levels

  Oxygen’s importance in cellular processes has long been known. But the work to understand how cells sense and adapt to changes in oxygen levels has led to medical insights and potential treatments for anemia, cancer, and more—and today, it has turned... Read more »

  Frank Vinluan10/7/19

• Bio Roundup: PARP Progress, A New Commish, IPO-Palooza & More

  It’s been a strange up and down ride for PARP inhibitors, a relatively new class of cancer drugs.

  Named for the tumor protein they target, PARPs rebounded after a big clinical setback in 2011 and have been at the center of... Read more »

  Ben Fidler10/4/19

• ESMO 2019: PARP and Prostate, SeaGen’s Win, KRAS Update & More

  The European Society for Medical Oncology meeting has wrapped up in Barcelona, the last major clinical cancer conference until December’s annual ASH meeting for blood diseases. We’ve highlighted a few top stories for you.

  Amid all the fuss over cell, gene,... Read more »

  Ben Fidler10/1/19

• Biotech Roundup: Vaping Toll Rises, NASH News, Akcea Shakeup & More

  Lung injuries linked to electronic cigarettes have topped 800 cases, including 12 deaths, according to the Centers for Disease Control and Prevention. Public health officials aren’t sure whether the injuries are from legally sold products made by companies such as... Read more »

  Frank Vinluan9/27/19

• Bio Roundup: Pelosi’s Reveal, Alder’s Deal, Biogen’s Fails & More

  Boston, San Francisco, and a few other metro areas might dominate the US life sciences, but some weeks, all bio-related eyes are on the nation’s capital. Health concerns about vaping continue to mount, and the feds could get involved. Meanwhile, try... Read more »

  Alex Lash9/20/19

• Pelosi, Dems Unveil Price Plan: Are 25 Drugs Enough for Negotiation?

  With the 2020 election just over a year away, House Speaker Nancy Pelosi (D-CA) has unveiled the Democratic Party’s answer to public discontent over high prescription drug prices.

  A preview of the plan was leaked last week. Today’s announcement doesn’t... Read more »

  Alex Lash9/19/19

• After First Look at House Drug Plan, Stocks Rise Slightly

  The first details of the long-awaited House Democrat plan to lower drug prices leaked out Monday night, with elements that have long been anathema to the biopharma industry and its supporters in Washington.

  While the world digested the details Tuesday, however,... Read more »

  Alex Lash9/10/19

Load More News ›

• Herceptin Inventors, Immunology Pioneers Take Home 2019 Lasker Awards

  This year’s Lasker Awards, the US’s most prestigious biomedical honor, are going to five scientists whose work led to a critical breast cancer treatment and significant basic research advances that have helped pave the way for immunotherapy.

  H. Michael Shepard, Dennis... Read more »

  Ben Fidler9/10/19

• At Big Lung Cancer Meeting, Lights Shine on KRAS, Drug Combos & More

  The treatment landscape for lung cancer has shifted significantly over the past few years, and more changes could be on the way. At the World Conference on Lung Cancer in Barcelona this weekend a number of drug makers trotted out... Read more »

  Ben Fidler9/9/19

• Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone

  Being first to market with a new type of drug brings advantages. The first mover sets the bar for what physicians, payers, and patients can expect of that medicine and how much it costs. It grabs market share that followers have... Read more »

  Frank Vinluan9/6/19

• With FDA’s Eye on JAK Drugs, Concert Moves One Ahead For Hair Loss

  Despite the safety concerns that have recently emerged for class of drugs known as JAK inhibitors, their reach continues to grow. The latest example comes from Concert Pharmaceuticals, which is racing the drug giant Pfizer to develop a medicine for a... Read more »

  Ben Fidler9/3/19

• Bio Roundup: Cholesterol Check, J&J’s Opioid Hit, AbbVie’s Flop & More

  You might be camping, barbecuing, or sleeping on Monday. It’s Labor Day, after all. But in Paris, this cardiologist will be in a conference center, walking an audience through a slide deck packed with Phase 3 data for a new cholesterol-lowering... Read more »

  Alex Lash8/30/19

• New PCSK9 Cholesterol Drug Faces Tough Foe. (Hint: Not Cholesterol.)

  [Updated 8/26/19, 10:30am. See below.] Remember when the new wave of expensive cholesterol-lowering drugs—known as PCSK9 inhibitors—was supposed to give the healthcare system a financial heart attack?

  Far from it. Four years after approval the two PCSK9 blockers... Read more »

  Alex Lash8/26/19

• Bio Roundup: Sarepta’s Stumble, Opioid Suits, Shkreli’s Legacy & More

  Biotech news tends to slow down in August but the past seven days have been busy for regulatory decisions. Three drugs and two devices won FDA nods.

  Not all companies were as fortunate. Several biotechs reported failed clinical trials or unfavorable... Read more »

  Frank Vinluan8/23/19

• Elanco’s $7.6B Deal With Bayer Bolsters Pets, Farm Animals Footprint

  Elanco Animal Health, the veterinary sector’s fourth-largest company measured by revenue, is poised to leap to number two through a $7.6 billion cash and stock deal for Bayer’s animal health unit.

  The acquisition will help Elanco boost its business selling products... Read more »

  Frank Vinluan8/20/19

• Bio Roundup: Zolgensma Fallout, Duchenne Redux, Ebola Boost & More

  We learned last week that the FDA was investigating Novartis for manipulating animal data related to its $2 million-a-dose gene therapy Zolgensma. The activity took place at AveXis, the firm Novartis bought for $8.7 billion in 2018, and Novartis reportedly... Read more »

  Alex Lash8/16/19

Read More Posts ›